OpenAlex
PricingAboutJobs
Log inGet started
Work

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

HTML

Year: 2021
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Hepatology
DOI: 10.1016/j.jhep.2021.01.047
Authors: Stephen A. Harrison, Mustafa R. Bashir, Kyoung-Jin Lee, Jennifer Shim-Lopez, Jonathan Lee, Brandee Wagner, Nicholas D. Smith, Hubert C. Chen, Eric J. Lawitz
Institutions: Pinnacle Clinical Research, Duke Medical Center, The University of Texas at San Antonio Health Science Center, Texas Liver Institute
Language: English

Topic: Liver Disease Diagnosis and Treatment
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: farnesoid X receptor agonist, nonalcoholic steatohepatitis, liver fat, structural optimization, alanine aminotransferase, pruritus, LDL cholesterol, HDL cholesterol, drug safety, NASH treatment, liver fibrosis, steatosis
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3128716033
FWCI: 11.27
Cites: 27
Cited by: 139
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security